Five things to know:
1. The European Union approved Medtronic’s Percept PC neurostimulator to treat symptoms of Parkinson’s disease, essential tremor, primary dystonia, epilepsy and obsessive-compulsive disorder.
2. The neurostimulator will be available in Western Europe beginning Jan. 15. Medtronic will launch the product in other regions based on local regulations.
3. Physicians using the system can detect and record patient-specific brain signals. The system’s BrainSense technology links these signals to patient-reported symptoms or side effects, facilitating personalized, data-driven neurostimulation treatment.
4. Other features of the Percept PC Deep Brain Stimulation system include low pulse width and improved battery life compared to Medtronic’s Activa PC neurostimulator. Percept PC is built to accommodate future software upgrades.
5. The product is currently under FDA review.
More articles on devices:
Dr. Bryan Little appointed to state medical board, task force
Former Medtronic, Bioventus executive becomes CEO at BlueWind Medical
Exactech co-founders retire, current CEO to transition to board role — 4 insights
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 18–20 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
